Cardiovascular events, such as cardiac arrhythmias, may be seen after the administration of muscarinic recepter antagonists and sympatho-mimetic agents, including umeclidinium/vilanterol. Therefore, Anoro Ellipta should be used with caution in patients with severe cardiovascular disease. 2
*At Week 8
**Spiolto is a trade mark of Boehringer Ingelheim
†Defined as ≥100 mL increase from baseline in trough FEV1 at Week 8 (p<0.001) vs. Spiolto.
ANORO and Ellipta are trademarks of the GSK group of companies.
ANORO Ellipta was developed in collaboration with Innoviva Inc.
Materials supplied by the above-country business unit to LOCs, for localisation must be subject to local Medical and/or Regulatory review and approval prior to external distribution.